1. In a network having routing elements for routing information through the network, a method for providing an ability to set up a Quality of Service (QoS) contract for a videoconference session between clients, the method comprising the steps of:
receiving a reservation for a time period for the videoconference session; and
sending configuration information to at least one of the routing elements after the time period is reserved for filtering real-time traffic corresponding to the videoconference session from other traffic traversing the network.
2. The method of claim 1, further comprising the step of registering, by the server, the clients for the videoconference session.
3. The method of claim 2, wherein said registering step comprises the step of receiving Internet Protocol (IP) addresses of each of the clients.
4. The method of claim 3, wherein said registering step further comprises the step of respectively associating the IP addresses of each of the clients with a unique identifier.
5. The method of claim 1, wherein the configuration information is sent using Simple Network Management Protocol (SNMP).
6. The method of claim 1, wherein the QoS contract specifies the average amount of bandwidth required by videoconference session traffic.
7. The method of claim 1, wherein the configuration information specifies a source Internet Protocol (IP) address and a destination IP address.
8. The method of claim 7, wherein the configuration information further specifies specific User Datagram Protocol (UDP) ports for the real-time traffic.
9. The method of claim 1, wherein the configuration information is a Type of Service (ToS) field bit set in an Internet Protocol (IP) header of an IP packet.
10. The method of step 1, further comprising the step of contacting the at least one of the routing elements to remove the configuration information upon an expiration of the reserved time period.
11. The method of claim 1, further comprising the steps of:
receiving a notification when the videoconference session has completed; and
contacting the at least one of the routing elements to remove the configuration information.
12. In a network having routing elements for routing information through the network, a system for providing an ability to set up a Quality of Service (QoS) contract for a videoconference session between clients, the system comprising:
means for receiving a reservation for a time period for the videoconference session; and
means for sending configuration information to at least one of the routing elements after the time period is reserved for filtering real-time traffic corresponding to the videoconference session from other traffic traversing the network.
13. The system of claim 12, further comprising means for registering the clients for the videoconference session.
14. The system of claim 13, wherein said means for registering comprises means for receiving Internet Protocol (IP) addresses of each of the clients.
15. The system of claim 14, wherein said means for registering further comprises means for respectively associating the IP addresses of each of the clients with a unique identifier.
16. The system of claim 12, wherein the configuration information is sent using Simple Network Management Protocol (SNMP).
17. The system of claim 12, wherein the QoS contract specifies the average amount of bandwidth required by videoconference session traffic.
18. The system of claim 12, wherein the configuration information specifies a source Internet Protocol (IP) address and a destination IP address.
19. The system of claim 18, wherein the configuration information further specifies specific User Datagram Protocol (UDP) ports for the real-time traffic.
20. The system of claim 12, wherein the configuration information is a Type of Service (ToS) field bit set in an Internet Protocol (IP) header of an IP packet.
21. The system of step 12, further comprising means for contacting the at least one of the routing elements to remove the configuration information upon an expiration of the reserved time period.
22. The system of claim 12, further comprising:
means for receiving a notification when the videoconference session has completed; and
means for contacting the at least one of the routing elements to remove the configuration information.
23. In a network having routing elements for routing information through the network, a method for providing an ability to set up a Quality of Service (QoS) contract for a videoconference session between clients, the method comprising the step of:
providing an ability to send a reservation for the videoconference session, the reservation specifying a time period for the videoconference session so that a client may participate in the videoconference session with a guaranteed level of service during the specified time period.
24. The method of claim 23, further comprising the step of providing an ability, to at least one of the clients, to register for the videoconference session.
25. The method of claim 24, wherein said step of providing the ability to register comprises the step of providing an ability to send an Internet Protocol (IP) address.
26. The method of claim 23, further comprising the step of providing an ability to send a notification of when the videoconference session has completed.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. A compound of Formula I
8
or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof
wherein
R1 is alkyl;
R2 is selected from the group consisting of aryl and heteroaryl;
the aryl or heteroaryl are optionally substituted;
n is 0-2;
A is selected from the group consisting of hydrogen, alkyl, and XR3;
R3 is alkyl or haloalkyl;
X is C(O) or S(O)p;
p is 1-2;
R4 and R5 are independently selected from the group consisting of hydrogen, alkyl and haloalkyl; or
R1 and R5 together with the ring to which they are attached form a 5-, 6- or 7-membered sulfur-containing ring with 1-2 double bonds and 0-2 oxo substituents; or
A and R4 together with the ring to which they are attached form a ring selected from the group consisting of a 5-, 6-, or 7-membered carbocyclic ring with 1-2 double bonds and 0-1 oxo substituents and a 5-, 6- or 7-membered sulfur-containing ring with 1-2 double bonds and 0-2 oxo substituents, provided that at least one of R1 and R5 or A and R4 forms a ring.
2. The compound according to claim 1 wherein A and R4 together with the ring to which they are attached form a 6-membered carbocyclic ring with 1 double bond and 1 oxo substituent.
3. The compound according to claim 2 wherein R1 and R5 together with the ring to which they are attached form a 6-membered sulfur-containing ringwith 1 double bond and 2 oxo substituents.
4. The compound according to claim 3 wherein R2 is an optionally substituted aryl.
5. The compound according to claim 4 selected from the group consisting of
3,4,6,7,8,10-hexahydro-10-phenyl-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-(3-nitrophenyl)-2H-thiopyrano 3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-cyanophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-3-(trifluoromethyl)phenyl-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-bromophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-chlorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-4-(trifluoromethyl)phenyl-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-bromophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3,4-dichlorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-chloro-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-bromo-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3,4-difluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-3-fluoro-5-(trifluoromethyl)phenyl-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-4-fluoro-3-(trifluoromethyl)phenyl-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-1 0-(4-methyl-3-nitrophenyl)2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-chloro-3-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-chloro-3-nitrophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide; and
3,4,6,7,8,10-hexahydro-10-(3,4,5-trifluorophenyl)-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide.
6. The compound according to claim 3 wherein R2 is an optionally substituted heteroaryl.
7. The compound according to claim 6 selected from the group consisting of
10-(3-pyridyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide; and
10-(4-pyridyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide.
8. The compound according to claim 2 wherein R1 and R5 together with the ring to which they are attached form a 5-membered sulfur-containing ringwith 1 double bond and 2 oxo substituents.
9. The compound according to claim 8 wherein R2 is an optionally substituted aryl.
10. The compound according to claim 9 selected from the group consisting of
9-(3-cyanophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3-nitrophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3,4-dichlorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-4-fluoro-3-(trifluoromethyl)phenyl-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
3,4,5,6,7,9-hexahydro-9-(4-methyl-3-nitrophenyl)thieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3,4-difluorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(4-chloro-3-nitrophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide; and
9-(3-bromo-4-fluorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide.
11. The compound according to claim 2 wherein R1 and R5 are alkyl.
12. The compound according to claim 11 wherein R2 is an optionally substituted aryl.
13. The compound according to claim 12 selected from the group consisting of
4-(3-cyanophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-4-(3-nitrophenyl)-5(1H)-quinolinone;
4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-4-4-(trifluoromethyl)phenyl-5 (1H)-quinolinone;
4-(3,4-dichlorophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4,6,7,8-tetrahydro-2-methyl-4-(4-methyl-3-nitrophenyl)-3-(methylsulfonyl)-5 (1H)-quinolinone;
4-(4-chloro-3-nitrophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4-(3-bromo-4-fluorophenyl)-4,6,7, 8-tetrahydro-2-methyl-3-(methylsulfonyl)-5 (1H)-quinolinone;
4-(4-chloro-3-fluorophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone; and
4-(3,4,5-trifluorophenyl)-4,6,7, 8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone.
14. The compound according to claim 1 wherein A and R4 together with the ring to which they are attached form a 5-membered carbocyclic ring with 1 double bond and 1 oxo substituent.
15. A compound according to claim 14 wherein R1 and R5 together with thering to which they are attached form a 6-membered sulfur-containing ring with 1 double bond and 2 oxo substituents.
16. A compound according to claim 15 wherein R2 is an optionally substituted aryl.
17. A compound according to claim 16 selected from the group consisting of
9-(3-cyano)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(3,4-dichlorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(4-chloro-3-nitrophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(3-chloro-4-fluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(3-bromo-4-fluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(4-fluoro-3-trifluoromethyl)-3,4,5,6,7,9-hexahydrocyclopentab-thiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide; and
9-(4-methyl-3-nitro)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano 2,3-epyridin-8(2H)-one, 1,1-dioxide.
18. The compound according to claim 14 wherein R1 and R5 together with the ring to which they are attached form a 5-membered sulfur-containing ring with 1 double bond and 2 oxo substituents.
19. The compound according to claim 18 wherein R2 is an optionally substituted aryl.
20. The compound according to claim 19 selected from the group consisting of
8-(4-chloro-3-nitrophenyl)-3,5,6,8-tetrahydro-2H-cyclopentabthieno2,3-epyridin-7(4H)-one, 1,1-dioxide; and
8-(3-bromo-4-fluorophenyl)-3,5,6,8-tetrahydro-2H-cyclopentabthieno2,3-epyridin-7(4H)-one, 1,1-dioxide.
21. The compound according to claim 1 wherein A is XR3, X is C(O), and R3 and R4 are alkyl.
22. The compound according to claim 21 wherein R1 and R5 together with the ring to which they are attached form a 6-membered sulfur-containing ringwith 1 double bond and-2 oxo substituents.
23. The compound according to claim 22 wherein R2 is an optionally substituted aryl.
24. The compound according to claim 23 selected from the group consisting of
1-8-(3,4-dichlorophenyl)-3,4,5,8-tetrahydro-6-methyl-1,1-dioxido-2H-thiopyrano3,2-bpyridin-7-ylethanone; and
1-8-(4-chloro-3-nitrophenyl)-3,4,5,8-tetrahydro-6-methyl-1,1-dioxido-2H-thiopyrano3,2-bpyridin-7-ylethanone.
25. The compound according to claim 1 wherein A and R4 together with the ring to which they are attached form a 6-membered sulfur-containing ring with 1 double bond and 0-2 oxo substituents.
26. The compound according to claim 25 wherein R1 and R5 together with the ring to which they are attached form a 6-membered sulfur-containing ring with 1 double bond and 0-2 oxo substituents.
27. The compound according to claim 26 wherein R2 is an optionally substituted aryl.
28. The compound according to claim 27 which is 10-(4-chloro-3-nitrophenyl)-3,4,6,7,10-hexahydro-2H,5H-bisthiopyrano3,2-b:2,3-epyridine, 1,1,9,9-tetraoxide.
29. A compound selected from the group consisting of
3,4,6,7,8,10-hexahydro-10-phenyl-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-(3-nitrophenyl)-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-cyanophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano 3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-3-(trifluoromethyl)phenyl-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-bromophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-chlorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-4-(trifluoromethyl)phenyl-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-bromophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3,4-dichlorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-chloro-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-bromo-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3,4-difluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-3-fluoro-5-(trifluoromethyl)phenyl-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-4-fluoro-3-(trifluoromethyl)phenyl-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-10-(4-methyl-3-nitrophenyl)2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-chloro-3-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-chloro-3-nitrophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
3,4,6,7,8,10-hexahydro-1 0-(3,4,5-trifluorophenyl)-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(3-pyridyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
10-(4-pyridyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano 3,2-bquinolin-9(5H)-one, 1,1-dioxide;
9-(3-cyanophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3-nitrophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3,4-dichlorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-4-fluoro-3-(trifluoromethyl)phenyl-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
3,4,5,6,7,9-hexahydro-9-(4-methyl-3-nitrophenyl)thieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3,4-difluorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(4-chloro-3-nitrophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
9-(3-bromo-4-fluorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
4-(3-cyanophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-4-(3-nitrophenyl)-5(1H)-quinolinone;
4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-4-4-(trifluoromethyl)phenyl-5(1H)-quinolinone;
4-(3,4-dichlorophenyl)-4,6,7, 8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4,6,7,8-tetrahydro-2-methyl-4-(4-methyl-3-nitrophenyl)-3-(methylsulfonyl)-5(1H)-quinolinone;
4-(4-chloro-3-nitrophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4-(3-bromo-4-fluorophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4-(4-chloro-3-fluorophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
4-(3,4,5-trifluorophenyl)-4,6,7,8-tetrahydro-2-methyl-3-(methylsulfonyl)-5(1H)-quinolinone;
9-(3-cyano)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(3,4-dichlorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(4-chloro-3-nitrophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(3-chloro-4-fluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(3-bromo-4-fluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(4-fluoro-3-trifluoromethyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
9-(4-methyl-3-nitro)-3,4,5,6,7,9-hexahydrocyclopentabthio-pyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
8-(4-chloro-3-nitrophenyl)-3,5,6,8-tetrahydro-2H-cyclopentabthieno2,3-epyridin-7(4H)-one, 1,1-dioxide;
8-(3-bromo-4-fluorophenyl)-3,5,6,8-tetrahydro-2H-cyclopentabthieno2,3-epyridin-7(4H)-one, 1,1-dioxide;
8-(3,4-dichlorophenyl)-3,4,5,8-tetrahydro-6-methyl-1,1-dioxido-2H-thiopyrano3,2-bpyridin-7-ylethanone;
1-8-(4-chloro-3-nitrophenyl)-3,4,5,8-tetrahydro-6-methyl-1,1-dioxido-2H-thiopyrano3,2-bpyridin-7-ylethanone; and
10-(4-chloro-3-nitrophenyl)-3,4,6,7,1 0-hexahydro-2H, 5H-bisthiopyrano3,2-b:2,3-epyridine, 1,1,9,9-tetraoxide, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
30. A method for treating a disease comprising administering an effective amount of the compound of claim 1.
31. The method of claim 30 wherein the disease is selected from the group consisting of asthma, epilepsy, hypertension, Raynaud’s syndrome, impotence, migraine, pain, eating disorders, urinary incontinence, functional bowel disorders, neurodegeneration and stroke.
32. A compound of formula II
9
or a pharmaceutically acceptable salt, ester, amide or prodrug thereof
wherein
R2 is selected from the group consisting of aryl and heteroaryl;
the aryl or heteroaryl are optionally substituted;
n is 1 or 2;
X is selected from the group consisting of CH2, C(O), S(O), or S(O)2; and
n and n are independently 1-3.
33. The compound according to claim 32 wherein R2 is an optionally substituted aryl.
34. The compound according to claim 33 wherein said substituted aryl is substituted with substituents selected from the group consisting of halo, nitro, cyano, and haloalkyl.
35. The compound according to claim 32 wherein R2 is an optionally substituted heteroaryl.
36. The compound according to claim 35 wherein said substituted heteroaryl is substituted with substituents selected from the group consisting of halo, nitro, cyano, and haloalkyl.
37. A compound of claim 32 selected from the group consisting of:
9-(3,4-Difluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
8-(4-Chloro-3-nitrophenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine, 1,1,7,7-tetraoxide;
8-(3-Cyanophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(3-Bromo-4-fluorophenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine, 1,1,7,7-tetraoxide;
10-(3-Bromo-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H,5H-dithiopyrano3,2-b:2,3-epyridine, 1,1,9,9-tetraoxide;
3,4,5,6,7,9-Hexahydro-9-(3-nitrophenyl)cyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
8-(3-Bromo-4-fluorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(4-fluoro-3-trifluoromethylphenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
2,3,4,5,6,8-Hexahydro-8-(3-nitrophenyl)-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
3,4,6,7,8,10-Hexahydro-1 0-(3-nitrophenyl)-2H,5H-dithiopyrano3,2-b:2,3-epyridine, 1,1,9,9-tetraoxide;
8-(3,4-Dichlorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno 2,3-epyridin-7-one, 1,1-dioxide;
8-(3-Chloro-4-fluorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(3-Cyanophenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine,
1,1,7,7-tetraoxide;
8-(2-Cyano-4-pyridinyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(3-Bromophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(4-Fluoro-3-trifluoromethylphenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine, 1,1,7,7-tetraoxide;
8-(4-Bromo-2-thienyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(5-Bromo-2-thienyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
2,3,4,5,6,8-Hexahydro-8-(5-nitro-3-thienyl)-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
2,3,4,5,6,8-Hexahydro-8-(5-nitro-2-thienyl)-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
2,3,4,5,6,8-Hexahydro-8-(5-nitro-2-furyl)-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(3,4-Dibromophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
2,3,4,5,6,8-Hexahydro-8-(3-nitrophenyl)dithieno3,2-b:2,31-epyridine, 1,1,7,7-tetraoxide;
8-(3-Chloro-4-fluorophenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine, 1,1,7,7-tetraoxide;
8-(3,4-Chlorophenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine, 1,1,7,7-tetraoxide;
8-(4-Bromophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(3,4-Difluorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
8-(4-Chloro-3-fluorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
9-(3-Chloro-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
8-(3-Cyano-4-fluorophenyl)-2,3,4,5,6,8-hexahydrodithieno3,2-b:2,3-epyridine, 1,1,7,7-tetraoxide;
()(9R)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
()(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
8-(2,1,3-Benzoxadiazol-5-yl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
()(8S)-8-(3-Bromo-4-fluorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
()(8R)-8-(3-Bromo-4-fluorophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
9-(2,1,3-Benzoxadiazol-5-yl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
9-(4-Fluoro-3-iodophenyl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
8-(4-Fluoro-3-iodophenyl)-2,3,4,5,6,8-hexahydro-7H-cyclopentabthieno2,3-epyridin-7-one, 1,1-dioxide;
() 9-(3-Bromo-4-fluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
() 9-(3-Bromo-4-fluorophenyl)-3,4,5,6,7,9-hexahydrocyclopentabthiopyrano2,3-epyridin-8(2H)-one, 1,1-dioxide;
() 10-(3-Bromo-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
() 10-(3-Bromo-4-fluorophenyl)-3,4,6,7,8,10-hexahydro-2H-thiopyrano3,2-bquinolin-9(5H)-one, 1,1-dioxide;
()(9R)-9-(3,4-Dichlorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
()(9S)-9-(3,4-Dichlorophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
()(9R)-9-(2,1,3-Benzoxadiazol-5-yl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
()(9S)-9-(2,1,3-Benzoxadiazol-5-yl)-2,3,5,6,7,9-hexahydrothieno3,2-bquinolin-8(4H)-one, 1,1-dioxide;
()(9R)-9-(4-chloro-3-nitrophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-95 bquinolin-8(2H)-one, 1,1-dioxide;
()(9S)-9-(4-chloro-3-nitrophenyl)-3,4,5,6,7,9-hexahydrothieno3,2-bquinolin-8(2H)-one, 1,1-dioxide;
11-(3-Bromo-4-fluorophenyl)-2,3,4,5,7,8,9,11-octahydrothiepino3,2-bquinolin-10(6H)-one, 1,1-dioxide; and
10-(3-Bromo-4-fluorophenyl)-2,3,4,5,6,7,8,10-octahydro-9H-cyclopentabthiepino2,3-epyridin-9-one, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.
38. A method for treating a disease comprising administering an effective amount of the compound of claim 32.
39. The method of claim 38 wherein the disease is selected from the group consisting of asthma, epilepsy, hypertension, Raynaud’s syndrome, impotence, migraine, pain, eating disorders, urinary incontinence, functional bowel disorders, neurodegeneration and stroke.
40. A method for treating a disease comprising administering an effective amount of the compound of claim 37.
41. The method of claim 40 wherein the disease is selected from the group consisting of asthma, epilepsy, hypertension, Raynaud’s syndrome, impotence, migraine, pain, eating disorders, urinary incontinence, functional bowel disorders, neurodegeneration and stroke.